Skip to Content
Merck

AB1056F

Anti-Adenovirus Antibody, FITC-conjugated

Chemicon®, from goat

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
FITC conjugate
Clone:
polyclonal
Application:
immunofluorescence
immunohistochemistry
Species reactivity:
human
Citations:
19
Technique(s):
immunofluorescence: suitable
immunohistochemistry: suitable

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Anti-Adenovirus Antibody, FITC-conjugated, Chemicon®, from goat

biological source

goat

conjugate

FITC conjugate

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable
immunohistochemistry: suitable

shipped in

wet ice

Quality Level

300

Application

Anti-Adenovirus Antibody, FITC-conjugated is an antibody against Adenovirus for use in IF, IH.
Direct FA staining of target antigens in a permissive tissue culture system. Suggested dilution: 1:10-1:50. Acetone fixation of the antigen source is recommended prior to staining.

Optimal working dilutions must be determined by end user
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Biochem/physiol Actions

Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Immunogen

Hexon from adenovirus type 5.

Physical form

IgG fraction conjugated to FITC. In PBS (0.01 M, pH 7.2) containing 10 mg/mL BSA and 0.1% sodium azide

Preparation Note

Maintain at 2-8°C for 3 months or at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Store under subdued light.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

AB1056F:

jan

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

N Yawata et al.
Mucosal immunology, 9(1), 159-170 (2015-06-18)
The most severe form of virus-induced inflammation at the ocular surface is epidemic keratoconjunctivitis (EKC), often caused by group D human adenoviruses (HAdVs). We investigated the dynamics and mechanisms of changes in natural killer (NK) cell types in the human
Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration.
F A Nunes, E E Furth, J M Wilson, S E Raper
Human Gene Therapy null
Hideki Yoshida et al.
Translational oncology, 14(2), 100997-100997 (2020-12-19)
The PAX3-FOXO1 fusion gene functions as a transactivator and increases expression of many cancer-related genes. These lead to metastases and other unfavorable outcomes for alveolar rhabdomyosarcoma (ARMS) patients. In order to target ARMS with the PAX3-FOXO1 transactivator, we developed an
Rachael Mooney et al.
Molecular therapy oncolytics, 12, 79-92 (2019-02-06)
Oncolytic virotherapy is a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the clinic has been hampered by rapid immune-mediated clearance or neutralization of the virus, which reduces viral access to tumor foci. To
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.
Daniel Stone, Ying Liu, Zong-Yi Li, Sebastian Tuve, Robert Strauss, Andre Lieber
Molecular Therapy null
View All Related Papers

Global Trade Item Number

SKUGTIN
AB1056F04053252740022

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service